ADVANCES, BENEFITS, AND CLINICAL CHALLENGES

Abstract

Semaglutide is a GLP-1 agonist widely used in the treatment of type 2 diabetes and obesity. Its mechanism of action improves glycemic control, reduces hunger, and leads to significant weight loss. Additionally, semaglutide lowers cardiovascular risk, making it a comprehensive therapeutic option for patients with metabolic comorbidities. However, challenges such as side effects, high costs, and off-label use for aesthetic purposes remain to be addressed. Accessibility to the drug remains a barrier for much of the population, highlighting the need for in-depth studies on its incorporation into public health systems. The future of semaglutide includes the development of new formulations and therapeutic combinations that may enhance its efficacy and safety.